Table 1 baseline characteristics and incidence of the outcome: Tehran Lipid and glucose study
|  | Men (N = 1310) | Women (N = 1960) | p |
|---|---|---|---|
Age (years) |  |  | < 0.001 |
 < 45 | 672 (51.3) | 1065 (54.34) |  |
 ≤ 45 to > 50 | 165 (12.6) | 258 (13.16) |  |
 ≤ 50 to > 55 | 121 (9.24) | 215 (10.97) |  |
 ≤ 55 to > 60 | 108 (8.24) | 177 (9.03) |  |
 ≤ 60 to > 65 | 73 (5.57) | 129 (6.58) |  |
 ≤ 65 to > 70 | 89 (6.79) | 70 (3.57) |  |
 ≤ 70 to > 75 | 60 (4.58) | 35 (1.79) |  |
 ≤ 75 to > 85 | 22 (1.68) | 11 (0.56) |  |
Total, mean (SD) | 47.1 (12.8) | 45.3 (11.3) | < 0.001 |
Body mass index (kg/m2) |  |  | < 0.001 |
 < 25 | 440 (33.59) | 394 (20.1) |  |
 ≤ 25 to < 30 | 615 (46.95) | 845 (43.11) |  |
 ≥ 30 | 255 (19.47) | 721 (36.79) |  |
 Total, mean (SD) | 26.8 (4.0) | 28.9 (4.6) | < 0.001 |
Waist circumference (cm) |  |  | < 0.001 |
 Men < 94 and women < 80 | 576 (43.97) | 307 (15.66) |  |
 Men ≥ 94 to < 102 and women ≥ 80 to < 88 | 410 (31.3) | 436 (22.24) |  |
 Men ≥ 102 and women ≥ 88 | 324 (24.73) | 1217 (62.09) |  |
 Total, mean (SD) | 94.9 (10.4) | 91.5 (11.6) | < 0.001 |
Use of antihypertensive medications (yes) | 42 (3.21) | 148 (7.55) | < 0.001 |
Current smoking (yes) | 406 (30.99) | 110 (5.61) | < 0.001 |
Family history diabetes (yes) | 440 (33.6) | 624 (31.8) | 0.29 |
Family history premature CVD (yes) | 231 (17.63) | 392 (20.0) | 0.01 |
Incidence of chronic cardio-metabolic disorders | 387 (29.54) | 929 (47.4) | < 0.001 |
T2DM | |||
 De novo detected T2DM at baseline | 64 (4.94) | 90 (4.66) | 0.71 |
 Incidence of T2DM | 105 (8.01) | 149 (7.6) | 0.62 |
CKD | |||
 De novo detected CKD at baseline | 53 (4.0) | 239 (12.2) | < 0.0001 |
 Incidence of CKD | 175 (13.3) | 547 (27.9) | < 0.0001 |
Incidence of CVD | 73 (5.57) | 49 (2.5) | < 0.001 |
Follow-up duration, median (IQR) | 6.26 (5.65–7.0) | 6.22 (5.56–7.0) | < 0.001 |